08-Aug-2015, Spontaneous, Patient/Consumer Serious report SHS (1-7VN2UN).
A Female patient (age unknown) reported she received COPAXONE (GLATIRAMER ACETATE, Product is or 
cannot be excluded as a Teva product). 
The patient took COPAXONE for MULTIPLE SCLEROSIS (GLATIRAMER ACETATE, dosing regimen 1: 20mg 
Injection, Unknown, from -Dec-2006, until --2014; dosing regimen 2: 40mg Injection, from --2014).
While on the suspect medication, the patient experienced RELAPSE (Serious, since --2006); GONE FROM 4 
LESIONS TO AROUND 16 (Not Serious); PML (Serious); LIVER FAILURE (Serious). The patient reported she had 
been on Copaxone since December 2006. I began the 3x a week last year when it was available. Since 2006, I 
typically get 2 relapses Both and I have gone from 4 lesions to aroun 16. Also, I do feel stuck with Copaxone 
because of safety concerns. Other drugs are causing PML AND liver failure. The patient was not in Shared 
Solutions at the time of the events. Follow-up declined.
At the time of the report the outcomes of the AEs were: RELAPSE: Unknown, PML: Unknown, LIVER FAILURE: 
Unknown, GONE FROM 4 LESIONS TO AROUND 16: Unknown.
Action taken with suspect drug: COPAXONE - Unknown.
The patient had medical history of MULTIPLE SCLEROSIS (Continuing).
The patient's concomitant medications were unspecified.
The patient's past medications were unspecified.
Lab tests were not reported.
This case was considered serious based on the following criteria: (Other Serious (Important Medical Events))
Teva Comment:  GLATIRAMER ACETATE - The events of relapse and gone from 4 lesions to around 16 are due 
to multiple sclerosis. Causality: Not related. The events of PML and liver failure are due to intercurrent illnesses. 
Causaltiy: Not related. 
Because this is a spontaneous case, regulatory distribution will be handled as though it is a related case.